PD‐L1 expression is associated with the spontaneous regression of patients with methotrexate‐associated lymphoproliferative disorders

Autor: Tadashi Yoshino, Naoya Nakamura, Misa Sakamoto, Tomoka Ikeda, Yuria Egusa, Yoshito Nishimura, Yasuharu Sato, Azusa Fujita, Misato Doi, Noriko Iwaki, Asami Nishikori, Midori Filiz Nishimura, Yuka Gion
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Male
rheumatoid arthritis
Cancer Research
medicine.medical_treatment
Remission
Spontaneous
Spontaneous remission
Kaplan-Meier Estimate
Gastroenterology
B7-H1 Antigen
Arthritis
Rheumatoid
Pathogenesis
programmed cell death‐ligand 1
rheumatoid arthritis
immune system diseases
hemic and lymphatic diseases
heterocyclic compounds
skin and connective tissue diseases
Research Articles
classic Hodgkin lymphoma
RC254-282
Aged
80 and over
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Middle Aged
Hodgkin Disease
Oncology
Antirheumatic Agents
Female
Lymphoma
Large B-Cell
Diffuse
Research Article
medicine.drug
Adult
musculoskeletal diseases
medicine.medical_specialty
methotrexate‐associated lymphoproliferative disorder
diffuse large B-cell lymphoma
Lymphoproliferative disorders
programmed cell death-ligand 1
Internal medicine
medicine
Humans
methotrexate-associated lymphoproliferative disorder
Radiology
Nuclear Medicine and imaging
Aged
Chemotherapy
business.industry
diffuse large B‐cell lymphoma
Clinical Cancer Research
medicine.disease
Lymphoma
Discontinuation
Methotrexate
business
Diffuse large B-cell lymphoma
Zdroj: Cancer Medicine, Vol 11, Iss 2, Pp 417-432 (2022)
Cancer Medicine
ISSN: 2045-7634
Popis: Background Most patients with methotrexate‐associated lymphoproliferative disorder (MTX‐LPD) show diffuse large B‐cell lymphoma (DLBCL) or classic Hodgkin lymphoma (CHL) types. Patients with MTX‐LPD often have spontaneous remission after MTX discontinuation, but chemotherapeutic intervention is frequently required in patients with CHL‐type MTX‐LPD. In this study, we examined whether programmed cell death‐ligand 1 (PD‐L1) expression levels were associated with the prognosis of MTX‐LPD after MTX discontinuation. Methods A total of 72 Japanese patients diagnosed with MTX‐LPD were clinicopathologically analyzed, and immunohistochemical staining of PD‐L1 was performed in 20 DLBCL‐type and 24 CHL‐type MTX‐LPD cases to compare with the clinical course. Results PD‐L1 was expressed in 5.0% (1/20) of patients with DLBCL‐type MTX‐LPD, whereas it was expressed in 66.7% (16/24) of the patients with CHL‐type MTX‐LPD in more than 51% of tumor cells. Most CHL‐type MTX‐LPD patients with high PD‐L1 expression required chemotherapy owing to exacerbations or relapses after MTX discontinuation. However, no significant differences in clinicopathologic findings at diagnosis were observed between PD‐L1 high‐ and low‐expression CHL‐type MTX‐LPD. Conclusion PD‐L1 expression was significantly higher in patients with CHL‐type than DLBCL‐type MTX‐LPD, suggesting the need for chemotherapy in addition to MTX discontinuation in CHL‐type MTX‐LPD patients to achieve complete remission. No association was observed between PD‐L1 expression levels and clinical findings at diagnosis, suggesting that PD‐L1 expression in tumor cells influences the pathogenesis of CHL‐type MTX‐LPD after MTX discontinuation.
Patients with classic Hodgkin lymphoma (CHL)‐type methotrexate‐associated lymphoproliferative disorder (MTX‐LPD) with high programmed cell death‐ligand 1 (PD‐L1) expression tended to have exacerbations and relapses after MTX discontinuation. Our study suggests that the PD‐1/PD‐L1 pathway may be involved in refractoriness to MTX discontinuation in CHL‐type MTX‐LPD.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje